Thymopoietin

Thymopoietin is a 49-amino acid thymic hormone produced by thymic epithelial cells, existing as isoforms (Thymopoietin I, II, and III). It plays a central role in T-lymphocyte differentiation and maturation, helping to establish and maintain cell-mediated immunity. Research has focused on its immunomodulatory properties in aging, immunodeficiency states, and as the parent protein from which the active pentapeptide Thymopentin (TP-5) was derived.

Thymopoietin acts on lymphoid progenitor cells to induce T-cell lineage commitment and differentiation markers. It suppresses neuromuscular transmission (early research linked it to myasthenia gravis) via acetylcholine receptor modulation. Its immunological actions are mediated through the active pentapeptide sequence (residues 32–36, Arg-Lys-Asp-Val-Tyr), which corresponds to Thymopentin. Full-length Thymopoietin is thought to interact with both immune cell receptors and nuclear lamina proteins in its role as a structural component.

Thymopoietin research established the concept of thymic hormonal control of T-cell development. Early studies in the 1970s–1980s by Gideon Goldstein's group characterized its structure and immunological activity. Later research led to isolation of the active TP-5 fragment. Interest has extended to Thymopoietin's role as a nuclear lamina protein (LAP2), with implications for progeria-like diseases and DNA repair. Modern immunotherapy research treats Thymopoietin as a historical benchmark for thymic peptide pharmacology.

Peptides commonly paired with Thymopoietin for synergistic effects.